Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease

Journal of Pharmacology and Experimental Therapeutics

Volumn 310, Issue 1, 2004, Pages 386-394

  Hill, Michael P ^a   Ravenscroft, Paula ^a   Bezard, Erwan ^b   Crossman, Alan R ^a,c   Brotchie, Jonathan M ^d   Michel, Anne ^e   Grimée, Renee ^e   Klitgaard, Henrik ^e  

^a Williams House   (United Kingdom)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMANTADINE; BENSERAZIDE PLUS LEVODOPA; ETIRACETAM; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOREA; CONTROLLED STUDY; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG POTENTIATION; DYSKINESIA; DYSTONIA; FEMALE; LOCOMOTION; MALE; MARMOSET; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

AMANTADINE; ANIMALS; ANTICONVULSANTS; ANTIPARKINSON AGENTS; CALLITHRIX; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; DYSKINESIAS; FEMALE; LEVODOPA; MALE; MPTP POISONING; PIRACETAM;

EID: 3042637096     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.066191     Document Type: Article

References (38)

1. Bezard E, Brotchie JM, and Gross CE (2001) Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2:577-588.
2. Bezard E, Ferry S, Mach U, Stark H, Leriche L, Boraud T, Gross CE, and Sokoloff P (2003) Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 9:762-767.
3. Bezard E, Hill MP, McGuire SG, Crossman AR, Brotchie JM, Michel A, Grimée R, and Klitgaard H (2004) Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. Eur J Pharmacol 485:159-164.
4. Blanchet PJ, Konitsiotis S, and Chase TN (1998) Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 13:798-802.
5. Boraud T, Bezard E, Bioulac B, and Gross C (2001) Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alteration of pallidal neurons in the MPTP-treated monkey. Brain 124:546-557.
6. Boraud T, Bezard E, Bioulac B, and Gross CE (2002) From single extracellular unit recording in experimental and human Parkinsonism to the development of a functional concept of the role played by the basal ganglia in motor control. Prog Neurobiol 66:265-283.
7. Brotchie JM and Fox SH (1999) Quantitative assessment of dyskinesias in subhuman primates. Mov Disord 14 (Suppl 1):40-47.
8. Butzer JF, Silver DE, and Sahs AL (1975) Amantadine in Parkinson's disease. A double-blind, placebo-controlled, crossover study with long-term follow-up. Neurology 25:603-606.
9. Chase TN and Oh JD (2000) Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol 47 (Suppl 1):S122-S130.
10. Cotzias GC, Papavasiliou PS, and Gellene R (1969) Modification of Parkinsonism-chronic treatment with L-dopa. N Engl J Med 280:337-345.
11. Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, and Bonuccelli U (2001) Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord 16:515-520.
12. Hayden FG, Gwaltney JM Jr, Van de Castle RL, Adams KF, and Giordani B (1981) Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults. Antimicrob Agents Chemother 19:226-233.
13. Heimer G, Bar-Gad I, Goldberg JA, and Bergman H (2002) Dopamine replacement therapy reverses abnormal synchronization of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of parkinsonism. J Neurosci 22:7850-7855.
14. Hill MP, Bezard E, McGuire S, Crossman AR, Grimée R, Brotchie JM, and Klitgaard H (2003) Novel anti-epileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Mov Disord 18:1301-1305.
15. Iravani MM, Jackson MJ, Kuoppamaki M, Smith LA, and Jenner P (2003) 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated primates. J Neurosci 23:9107-9115.
16. Klitgaard H, Matagne A, Grimee R, Vanneste-Goemaere J, and Margineanu DG (2003) Electrophysiological, neurochemical and regional effects of levetiracetam in the rat pilocarpine model of temporal lobe epilepsy. Seizure 12:92-100.
17. Klockgether T and Turski L (1990) NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann Neurol 28:539-546.
18. Kornhuber J, Bormann J, Hubers M, Rusche K, and Riederer P (1991) Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 206:297-300.
19. Macchio GJ, Ito V, and Sahgal V (1993) Amantadine-induced coma. Arch Phys Med Rehabil 74:1119-1120.
20. Magazanik LG, Antonov SM, Lukomskaya N, Potap'eva NN, Gmiro VE and Johnson J (1996) Blockade of glutamate- and cholinergic ion channels by amantadane derivatives. Neurosci Behav Physiol 26:13-22.
21. Margineanu DG and Klitgaard H (2000) Inhibition of neural hypersynchrony in vitro differentiates levetiracetam from classic antiepileptic drugs. Pharmacol Res 42:281-285.
22. Margineanu DG and Klitgaard H (2002) Levetiracetam: mechanisms of action, in Antiepileptic Drugs, 5th ed (Levy RH ed) pp 419-427, Lippincott Wiliams & Wilkins, Philadelphia.
23. Marson AG, Hutton JL, Leach JP, Castillo S, Schmidt D, White S, Chaisewikul R, Privitera M, and Chadwick DW (2001) Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res 46:259-270.
24. Mizoguchi K, Yokoo H, Yoshida M, Tanaka T, and Tanaka M (1994) Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-D-aspartate antagonism. Brain Res 662:255-258.
25. Morelli M, Fenu S, and Di Chiara G (1992) Blockade of N-methyl-D-aspartate receptors potentiates dopaminergic responses in the 6-OHDA model of Parkinson: differential role of D-1 and D-2 receptors. Neurochem Int 20:261S-264S.
26. Nini A, Feingold A, Slovin H, and Bergman H (1995) Neurons in the globus pallidus do not show correlated activity in the normal monkey, but phase-locked oscillations appear in the MPTP model of parkinsonism. J Neurophysiol 74:1800-1805.
27. Papa SM, Boldry RC, Engber TM, Kask AM, and Chase TN (1995) Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 701:13-18.
28. Papa SM and Chase TN (1996) Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 39:574-578.
29. Pearce RK, Jackson M, Smith L, Jenner P, and Marsden CD (1995) Chronic L-dopa administration induces dyskinesias in the MPTP-treated common marmoset (Callithrix Jacchus). Mov Disord 10:731-740.
30. Raz A, Frechter-Mazar V, Feingold A, Abeles M, Vaadia E, and Bergman H (2001) Activity of pallidal and striatal tonically active neurons is correlated in MPTP-treated monkeys but not in normal monkeys. J Neurosci 21:RC128(121-125).
31. Raz A, Vaadia E, and Bergman H (2000) Firing patterns and correlations of spontaneous discharge of pallidal neurons in the normal and the tremulous 1-methyl-4-phenyl-1,2,3,6-tetrahydropyr/dine vervet model of parkinsonism. J Neurosci 20:8559-8571.
32. Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, and Brotchie JM (2003) Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 18:872-883.
33. Snow BJ, Macdonald L, McAuley D, and Wallis W (2000) The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 23:82-85.
34. Stocchi F, Nordera G, and Marsden CD (1997) Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Clin Neuropharmacol 20:95-115.
35. Takahashi T, Yamashita H, Zhang YX, and Nakamura S (1996) Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum. Brain Res Bull 41:363-367.
36. Verhagen Metman L, Blanchet PJ, van den Munckhof P, Del Dotto P, Natte R, and Chase TN (1998a) A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov Disord 13:414-417.
37. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, and Chase TN (1998b) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50:1323-1326.
38. Wullner U, Kupsch A, Arnold G, Renner P, Scheid C, Scheid R, Oertel W, and Klockgether T (1992) The competitive NMDA antagonist CGP40.116 enhances L-dopa response in MPTP-treated marmosets. Neuropharmacology 31:713-715.